InvestorsHub Logo
icon url

BuyMyAsk

04/27/15 2:37 PM

#6965 RE: caesare74 #6964

Did you just try to inform me this was a long term story? I am prob one of the longest shareholders in this company and on these boards.

The Company has lost its luster big time. When they put out that pumped newsletter stating they were going to try for EAP the market sold this down as people are waiting (prob the institutions) to get out whole. I strongly feel this will continue to fall and test $6.80 again.

Management hasn't put a trial together in 6 YEARS!!! Now they are on the NASDAQ. People can short this stock and call their bluff.
icon url

pharmeng

04/27/15 6:39 PM

#6977 RE: caesare74 #6964

Where are you getting approval by US authority this June/July?

FDA approval is 1H 2017 at earliest. For cardiac surgery, the initial trial is 20 treated patients, 20 untreated, and plans to be be completed later this year. Expansion and completion of that trial could start end of this year, but would still likely require most of 2016 to complete. Then submission, I think even 510k requires 90 days for FDA to review. PMA probably longer (not as familiar with devices).

Even if they pursue EAP with a small sepsis trial. It would take time to select sites, start up, so probably Q4 2015.

Just guesses, but they have not historically moved very quickly on clinical trials.